The quarterly trajectory is genuinely the most interesting number in this file and the synthesis layer underweights it. Revenue went $82.9M → $84.7M → $86.7M → $100.1M → $108.4M → $117.7M over six quarters — that's a step-function, not a glide path. The March 2026 quarter is up 42% YoY off the comparable $82.9M base, far above the 13.8% "recent YoY" the momentum layer cites (which is using stale annual math). Gross margin at 67% is healthy for a diagnostics platform, and the operating line has flipped: Q1 2026 net income of $2.8M is the first clean profit quarter excluding the $78M tax-benefit-driven Q4 2024 print that distorts every TTM ratio in this file (including the EV/EBITDA of 111 and ROE of -2.6%). FY2025 operating loss of $21M against $42M of operating cash flow tells you working capital and stock-based comp are doing real work, but $36M FCF on a $1.18B market cap is a ~3% FCF yield on a business compounding revenue at 16%+ — that's not obviously expensive.

Where I disagree with the prior models: the synthesis verdict of "High Conviction Required" and Market Forces' "Neutral" both feel anchored to the 2023-2024 noise rather than the 2025-2026 inflection. The narrative layer calling this "unanchored / turnaround-bet" is the most wrong read — at 2.5x EV/revenue with accelerating top-line, expanding gross margin, and positive FCF, this is actually closer to fundamentals-anchored than story-anchored. The bear narrative ("15 years of capital sink, stubbornly low adoption") is backward-looking; the revenue print directly contradicts it. The classification confidence of 0.36 for "pre-profit growth" is appropriately low — CDNA is arguably transitioning out of that bucket right now, which is exactly when these archetypes mislead.

The contrarian case is real, though. First, the Q4 2024 $78M net income spike was almost certainly a deferred tax asset valuation allowance release, not operating performance — and the fact that 2025 reverted to a $21M loss confirms the underlying business was not yet profitable on a GAAP basis last year. Second, the revenue acceleration in late 2025/early 2026 may reflect a one-time AlloSure reimbursement catch-up or Medicare LCD resolution rather than structural volume growth — I'd want the 10-Q breakdown of test volume vs. ASP before extrapolating. Third, insider activity is unambiguously one-directional: every transaction in the last six weeks is a sale or in-kind tax withholding, zero open-market buys, including sales after the strong Q1 print. That's not what insiders do when they think the next four quarters will surprise upward. Fourth, the "competitors can enter if TAM proves real" risk is non-trivial — Natera (NTRA) has been pushing into transplant with Prospera, and if dd-cfDNA becomes a two-player market the pricing power thesis weakens fast. Fifth, balance sheet detail is thin in this file ($65M cash, debt unreported) — I can't fully size downside without knowing the convertible notes situation.

Net: I dissent from the synthesis "High Conviction Required" framing toward a more constructive view. At $22.8 and $1.18B market cap, you're paying ~2.5x EV/revenue for a business that just printed $117.7M in a quarter (annualizes to $470M+, putting forward EV/sales closer to 2.0x) with 67% gross margin, positive FCF, and a clinical moat in kidney transplant monitoring. If 2026 revenue lands at $470-490M with mid-single-digit operating margin, you're looking at 3.5x forward EV/sales on an accelerating, FCF-positive diagnostics platform — that's cheap relative to peers like NTRA (8x+) and EXAS (4x+). Fair value range $28-34 on a 12-month basis if Q2 confirms the acceleration; downside to $16-18 if Q2 decelerates back to $100M and reveals the spike was reimbursement timing. The insider selling and the unproven sustainability of the inflection mean this is a starter-position-and-add-on-confirmation setup, not a full-conviction buy. The narrative layer's "turnaround-bet" framing is stale by two quarters.